August 4, 2025 – Bounce Mobile Systems Inc. (OTC: BNCM) today announced a highly optimistic outlook
for its stock price, underpinned by the exceptional performance and strategic
expansion of its fully integrated subsidiary, Delex Healthcare Group Inc. The
company asserts that Delex’s rapid growth and increasing market share in the
dynamic Philippine healthcare sector are significant catalysts for enhanced
shareholder value.
Since the successful merger in October 2024, BNCM's
trajectory has become intrinsically linked to Delex Healthcare Group’s
burgeoning success. Delex Pharma, a pivotal component of the group, is
demonstrating robust financial and operational performance that is expected to
directly translate into a substantial increase in its valuation.
Key Factors Underpinning BNCM's Potential Stock
Price Growth:
- Accelerated Revenue Growth from Delex Pharma: Delex Pharma's strategic initiatives are
already yielding impressive results. The launch of 11 new pharmaceutical
products in the first half of 2024, including high-demand critical care,
oncology, and anesthesia drugs, is projected to contribute an additional
20% to Delex Pharma's total revenue in 2024. This aggressive product
pipeline, coupled with new distributorship agreements with global medical
device leaders, positions Delex for sustained, strong top-line growth.
- Rapid Expansion in a High-Growth Market: Delex Pharmacy is on track to expand from its
current three branches to 60 nationwide in the coming years, with
5-10 new stores anticipated to open in 2025 alone. This expansion
capitalizes on the Philippine pharmacy market's projected 3.77% CAGR
from 2024 to 2029. Furthermore, Delex is strategically leveraging the
medical device market, which is forecast to grow at an 8.14% CAGR from
2024 to 2029, reinforcing its position as a key player.
- Strong Financial Performance and Market
Presence:
Delex's impressive operational performance is reflected in its reported US$7,974,848.74
in total revenue and US$4,840,483.97 in gross profit for the nine
months ending September 30, 2024, with net assets standing at US$98,343,052.27.
The company's expansive distribution network, supplying nearly 700
hospitals and having a presence in over 900 Mercury Drug branches, ensures
widespread access and market penetration.
- Strategic Acquisition and Diversification: The acquisition of JMN Brothers Pharma
Limited, Inc., specializing in women's health and ethical hospital
products, and the establishment of a new oncology division, further
diversify Delex's revenue streams and strengthen its competitive advantage
in high-growth segments.
- Industry Recognition and Leadership: Delex Healthcare Group's CEO, Mr. J. De
Ruyter C. Oroceo, was recently honored as "CEO of the Year,"
while the company itself received "Philippines' Best Employer Brand
Award" and "Philippines' Brand Leadership Award." Such
accolades enhance corporate reputation and investor confidence.
"The fundamental strength and aggressive
growth trajectory of Delex Healthcare Group are set to unlock significant value
for BNCM shareholders," stated Paul Hatadi, CEO of BNCM. "The
consistent expansion of our product portfolio, the strategic widening of our
distribution channels, and our unwavering commitment to innovation and market
leadership in the burgeoning Philippine healthcare sector provide a compelling
foundation for a substantial increase in BNCM’s stock price. We are executing a
clear strategy that aligns our operational successes directly with shareholder
returns."
BNCM is focused on maximizing the synergistic
potential of its integrated operations, confident that the ongoing strong
performance of Delex Healthcare Group will lead to a re-evaluation of its stock
and considerable appreciation for investors.
About Bounce Mobile
Systems, Inc. (BNCM)
On July 2nd. In 2024, the Board of Directors of Delex Healthcare Group Inc. (DELEX) and Bounce
Mobile Systems Inc. (BNCM) signed an agreement for the merger between DELEX
and BNCM.
About Delex Healthcare
Group Inc. (DELEX)
DELEX is a leading
pharmaceutical company in the Philippines, engaged in the development,
marketing, and distribution of a wide range of pharmaceutical and healthcare
products. DELEX is committed to providing quality and affordable medicines and
medical devices, with a strong focus on critical care, anti-infectives,
anesthesia, oncology, and women's health.
For more Information
Email : info@bncm.us
Website : https://bncm.us
Disclaimer: The information presented in this article is for informational
purposes only and does not constitute financial, investment, or business
advice. BNCM and DELEX plans, projections, and growth strategies are
subject to various risks and uncertainties, and actual results may differ
significantly. Investors should conduct their own research and consult with a
financial advisor before making any investment decisions. BNCM and DELEX are
not responsible for any financial or investment outcomes resulting from the use
of this information.
Translate
